Key result
Beta-adrenergic blocking agents improve symptoms, left ventricular function, and reduce cardiovascular hospitalization and mortality in patients with chronic heart failure class II to IV.
Why the study?
Do beta-adrenoceptor blocking agents improve outcomes in patients with chronic heart failure class II to IV due to systolic ventricular dysfunction?
Population
Patients with chronic heart failure class II to IV due to systolic ventricular dysfunction
Design
Review
Authors
Loading...
Supports beta-blocker use in symptomatic HFrEF; reinforces consensus from prior randomized trials.
Do beta-adrenoceptor blocking agents improve outcomes in patients with chronic heart failure class II to IV due to systolic ventricular dysfunction?
This review summarizes the evidence supporting the use of beta-blockers in chronic heart failure with reduced ejection fraction to improve symptoms, reduce hospitalizations, and decrease mortality.
Batlouni et al. (2000) conducted a review in Heart failure. Beta-adrenergic blocking agents (metoprolol, bisoprolol, carvedilol) was evaluated. Beta-adrenergic blocking agents improve symptoms, left ventricular function, and reduce cardiovascular hospitalization and mortality in patients with chronic heart failure class II to IV.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: